Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of BCRP Q141K on Allopurinol PK/PD
NCT02956278Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Nov 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, double-blind trial of allopurinol in gout and hyperuricemia (3 arms), sponsored by University of California, San Francisco. Primary endpoints: Oxypurinol Renal Clearance at 24 hours and Percent Change in Uric Acid at 24 hours. Started Nov 2016; status: completed.
02
Drugs
allopurinol
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02956278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956278.